Methylprednisolone Acetate for Intra‑Articular Injections: Evidence‑Based Recommendations
Indications for Use
- The knee is the joint most frequently injected with intra‑articular methylprednisolone for osteoarthritis and inflammatory arthritis, reflecting its prevalence in clinical practice. 1
- Acute flares of knee pain, particularly when accompanied by joint effusion, are a primary indication for a single intra‑articular methylprednisolone injection. 1
- Acute gouty arthritis involving one or two large joints (e.g., knee, ankle) can be managed with intra‑articular methylprednisolone. 6
- Inflammatory arthritis of grade 1 affecting two or fewer joints, unresponsive to NSAIDs and low‑dose oral prednisone, is an appropriate scenario for intra‑articular methylprednisolone therapy. 3
Efficacy and Duration of Benefit
- A 40 mg intra‑articular methylprednisolone dose in the knee yields short‑term pain relief lasting 1–4 weeks; this benefit is supported by randomized evidence. 1
- Across knee osteoarthritis trials, intra‑articular corticosteroids produce a mean effect size of 1.27 for pain reduction versus placebo, confirming clinically meaningful short‑term efficacy. 4
- The therapeutic effect diminishes by 12–24 weeks, indicating that intra‑articular methylprednisolone is best reserved for acute symptom flares rather than long‑term disease control. 2
Injection Technique
- Ultrasound guidance improves the accuracy of intra‑articular needle placement, reducing the risk of treatment failure due to extra‑articular injection. 5
Safety Precautions
- Injections should only be performed after a definitive diagnosis is established and all contraindications (e.g., infection, coagulopathy) are excluded. 5
- Patients with diabetes should monitor blood glucose for the first three days after injection, as transient hyperglycemia is common. 5
Re‑Injection Considerations
- The decision to repeat an intra‑articular methylprednisolone injection should be individualized, weighing the magnitude and duration of prior benefit against potential risks. 5
- Patients should avoid excessive use of the injected joint for at least 24 hours post‑procedure, but routine immobilization is not recommended. 5